# Thermodynamic coupling between folding correctors and the first of dimerized nucleotide binding domains in CFTR

## TL;DR

This paper explores how folding correctors help fix a common cystic fibrosis mutation by stabilizing a key protein domain.

## Contribution

The study reveals a thermodynamic protective mechanism of folding correctors in posttranslational CFTR NBD1 folding.

## Key findings

- Folding correctors allosterically protect the α-subdomain of dimerized NBD1 from misfolding.
- Cooperative folding between α- and β-subdomains is the last step upon ivacaftor binding.
- The mechanism may restore Mg/ATP-mediated NBD dimerization in F508del mutation.

## Abstract

The most common cystic fibrosis mutation is the F508del mutation in the human cystic fibrosis transmembrane conductance regulator (hCFTR), which causes misfolding of the first of two nucleotide binding domains (NBD1/2), preventing Mg/ATP-dependent NBD dimerization for normal function. Although folding correctors elexacaftor/VX-445 and lumacaftor/VX-809 have been combined to correct the NBD1 misfolding, the exact correction pathway is still unknown. In this study, the constrained tertiary noncovalent interaction networks or the thermoring structures of dimerized NBD1 in hCFTR/E1371Q with or without F508del were analyzed to identify the weakest noncovalent bridge as the final posttranslational tertiary folding of dimerized NBD1 in response to folding correctors. These computational analyses suggested that hCFTR may primarily use cooperative folding between α- and β-subdomains in dimerized NBD1 as the last step upon the binding of the potentiator ivacaftor/VX-770. However, the binding of folding correctors may allosterically protect the α-subdomain from misfolding until subsequent core formation. This thermodynamic protective mechanism, unlike the chaperone-based one in cotranslational NBD1 folding, may restore posttranslational NBD1 folding for tight Mg/ATP-mediated NBD dimerization in the F508del mutation, and also potentially apply to treating other cystic fibrosis patients with rare mutations.